BB
BBIO
BBIO What BridgeBio Pharma promised, and what happened
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 12 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Infigratinib PROPEL 3 data presentation | presenting the full PROPEL 3 data set | Mar 2026 | we presented our Phase III PROPEL 3 results at the International Conference on Children's Bone Health (sic) [ International Congress of Children s Bone Health ] on June 30 and simultaneously published them in The New England Journal of Medicine | Achieved |
| Gondola Bio EPP program Phase III data | Phase III data | Mar 2025 | Our program in EPP announced positive Phase IIa data in June. And following a productive EOP2 meeting with the agency, we will be initiating a Phase IIb/III study in Q3 of this year. | Delayed |
| Attruby Afib data presentation | present the first results at ESC | Mar 2025 | Ghosted |
The full ledger
Open BridgeBio Pharma’s full ledger
A free account opens 5 company ledgers a month. All 21 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 21 tracked commitments for BridgeBio Pharma
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.